Torrent Pharmaceuticals has completed the redemption of secured redeemable non-convertible debentures (NCDs) worth ₹142.84 crores on December 12, 2025. The pharmaceutical company informed both BSE and NSE about this corporate action through an official communication.

Debenture Redemption Details

The redemption covers a portion of the company's debt securities, with key parameters outlined below:

The redeemed amount represents 14.28% of the total non-convertible debentures issued by the company under the specified ISIN.

Regulatory Compliance

Torrent Pharmaceuticals has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company notified both major stock exchanges where its shares are listed:

• BSE Limited (Scrip Code: 500420)
• National Stock Exchange of India (Scrip Code: TORNTPHARM)

The redemption and repayment were completed as scheduled. Company Secretary Chintan M. Trivedi signed the official communication to the exchanges.

Financial Impact

This redemption reduces the company's outstanding debt by ₹142.84 crores, leaving approximately ₹857.16 crores in NCDs still outstanding from the original ₹1,000 crores issue.

Torrent Pharmaceuticals Limited has received an Environmental, Social, and Governance (ESG) rating of 70 from NSE Sustainability Ratings and Analytics Limited. The pharmaceutical company announced this development through a regulatory filing dated December 10, 2025.

ESG Rating Details

The rating was independently assigned by NSE Sustainability Ratings and Analytics Limited, which operates as a SEBI-registered ESG rating provider. The assessment evaluates companies across three key dimensions of sustainable business practices.

Regulatory Compliance

Torrent Pharmaceuticals communicated this rating assignment to both major Indian stock exchanges in compliance with regulatory requirements. The notification was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III.

The company also referenced SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, indicating adherence to updated disclosure norms for ESG-related information.

Stock Exchange Communication

The pharmaceutical company filed the ESG rating disclosure with both BSE Limited and National Stock Exchange of India Limited. Company Secretary Chintan M. Trivedi signed the regulatory communication on behalf of Torrent Pharmaceuticals Limited.

ESG ratings have become increasingly important for listed companies as investors and stakeholders focus on sustainable business practices and corporate responsibility metrics.